Piccina Cintia — SEC insider filings
SEC reporting owner CIK 1907199. 10 insider filings on record with FilingPulse; latest filed 2026-09-03.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2022-01-31 to 2026-09-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 5 legs across 5 filings — 77,165 shares, $105,507 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: sale of 21,040 shares @ $1.77 ($37,314) in Adaptimmune Therapeutics PLC, filed 2022-08-01.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Adaptimmune Therapeutics PLC (ADAP) | Chief Commercial Officer | 8 | — | 4 legs · 70,452 sh · $89,825 | 10 |
| Autolus Therapeutics plc (AUTL) | U.S. CCO & Country Gen Manager | 1 | — | 1 leg · 6,713 sh · $15,682 | 2 |
| Allovir, Inc. (ALVR) | Chief Commercial Officer | 1 | — | — | 2 |
Insider filings — Piccina Cintia
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-03 | 4 | Autolus Therapeutics plc (AUTL) | Option exercise (M): 20,000 @ $2.35 · Sale (S): 6,713 @ $2.34 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Grant/award (A): 1,612,032 (derivative) @ $0 · Grant/award (A): 1,074,696 (derivative) @ $0 | EDGAR |
| 2025-01-15 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 12,991 @ $0.57 | EDGAR |
| 2024-06-18 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 24,531 @ $0.93 | EDGAR |
| 2024-03-18 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Grant/award (A): 5,088,864 (derivative) @ $0 · Grant/award (A): 1,130,832 (derivative) @ $0 | EDGAR |
| 2023-07-05 | 4 | Allovir, Inc. (ALVR) | Grant/award (A): 147,000 @ $0 · Grant/award (A): 273,000 (derivative) @ $0 | EDGAR |
| 2023-01-31 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 11,890 @ $1.87 | EDGAR |
| 2023-01-17 | 4 | Adaptimmune Therapeutics PLC | Grant/award (A): 1,407,072 (derivative) @ $0 · Grant/award (A): 314,256 (derivative) @ $0 · Grant/award (A): 181,560 (derivative) @ $0 | EDGAR |
| 2022-08-01 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 21,040 @ $1.77 | EDGAR |
| 2022-01-31 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Grant/award (A): 3,376,992 (derivative) @ $0 · Grant/award (A): 754,200 (derivative) @ $0 · Grant/award (A): 335,184 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2022-01-20 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1907199 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs